Art in sub-saharan africa: The value of viral load monitoring

The Lancet HIV

Volumn 2, Issue 7, 2015, Pages e261-e262

  Sigaloff, Kim C E ^a,b,c   de Wit, Tobias F Rinke ^a,c  

^a AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^b Division of Infectious Diseases   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA SOUTH OF THE SAHARA; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PUBLIC HEALTH; TREATMENT FAILURE; VIRUS LOAD; DRUG MONITORING; DRUG SUBSTITUTION; FEMALE; HIV INFECTIONS; MALE; STATISTICS AND NUMERICAL DATA;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTI-HIV AGENTS; DRUG MONITORING; DRUG SUBSTITUTION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84947035249     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(15)00109-5     Document Type: Note

References (13)

1. WHO. HIV/AIDS: data and statistics. May, 2015. http://www.who.int/hiv/ data/en/ (accessed May 20, 2015).
2. UNAIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. October, 2014. http://www.unaids.org/en/resources/documents/2014/90-90-90 (accessed May 29, 2015).
3. Renaud-Théry F, Avila-Figueroa C, Stover J, et al. Utilization patterns and projected demand of antiretroviral drugs in low- and middle-income countries. AIDS Res Treat 2011; 2011: 749041.
4. Haas AD, Keiser O, Balestre E, et al, for IeDEA southern Africa, east Africa, and west Africa. Monitoring and switching of fi rst-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis. Lancet HIV 2015; published online June 17. http://dx.doi.org/10.1016/S2352-3018(15)00087-9.
5. Keiser O, Tweya H, Boulle A, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009; 23: 1867-74.
6. Sigaloff KCE, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations: two arguments for viral load monitoring in Africa. J Acquir Immune Defi c Syndr 2011; 58: 23-31.
7. Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009; 23: 697-700.
8. Médecins Sans Frontières. Issue brief: achieving undetectable-what questions remain in scaling-up HIV virologic treatment monitoring? Nov 19, 2014. http://www.msfaccess.org/content/issue-brief-achievingundetectable-what-questions-remain-scaling-hiv-virologic-treatment (accessed May 29, 2015).
9. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization, 2013.
10. Keebler D, Revill P, Braithwaite S, et al. Cost-eff ectiveness of diff erent strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. Lancet Glob Health 2014; 2: e35-43.
11. Nichols BE, Sigaloff KCE, Kityo C, et al. Increasing the use of second-line therapy is a cost-eff ective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study. J Int AIDS Soc 2014; 17: 1-9.
12. Hamers RL, Sawyer AW, Tuohy M, Stevens WS, Rinke de Wit TF, Hill AM, for the ART-A Consortium. Cost-eff ectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS 2012; 26: 1663-72.
13. Rutstein SE, Hosseinipour MC, Kamwendo D, et al. Dried blood spots for viral load monitoring in Malawi: feasible and eff ective. PLoS One 2015; 10: e0124748.